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he molecular basis for the inverse relationship be-
tween differentiation and tumorigenesis is unknown.
The function of runx2, a master regulator of osteo-
blast differentiation belonging to the 
 
runt
 
 family of tumor
suppressor genes, is consistently disrupted in osteosarcoma
cell lines. Ectopic expression of runx2 induces p27
 
KIP1
 
,
thereby inhibiting the activity of S-phase cyclin complexes
and leading to the dephosphorylation of the retinoblas-
toma tumor suppressor protein (pRb) and a G1 cell cy-
cle arrest. Runx2 physically interacts with the hypophos-
phorylated form of pRb, a known coactivator of runx2,
T
 
thereby completing a feed-forward loop in which pro-
gressive cell cycle exit promotes increased expression of
the osteoblast phenotype. Loss of p27
 
KIP1
 
 perturbs transient
and terminal cell cycle exit in osteoblasts. Consistent with
the incompatibility of malignant transformation and per-
manent cell cycle exit, loss of p27
 
KIP1
 
 expression correlates
with dedifferentiation in high-grade human osteosarcomas.
Physiologic coupling of osteoblast differentiation to cell
cycle withdrawal is mediated through runx2 and p27
 
KIP1
 
,
and these processes are disrupted in osteosarcoma.
 
Introduction
 
Osteosarcoma is the most common bone cancer in young
adults, and a leading cause of cancer death in this age group.
Loss of differentiation has powerful prognostic significance in
osteosarcoma, with well-differentiated tumors being classified
as low-grade and dedifferentiated tumors usually falling into
the high-grade category. In one large series, 81% of osteosar-
comas were either poorly differentiated or undifferentiated
(Dahlin, 1957), and a late marker of osteogenic differentia-
tion, osteocalcin, was undetectable in 
 

 
75% of osteosarcomas
(Hopyan et al., 1999). In vitro data support the view that osteo-
blast differentiation is antagonistic to oncogenic processes.
Cellular immortalization attenuates expression of osteoblast
phenotype (Bodine et al., 1996; Feuerbach et al., 1997),
whereas osteoblast differentiation is associated with progres-
sive loss of proliferative capacity, culminating in terminal cell
cycle exit (Stein et al., 1996; Aubin, 1998). Although it is clear
that differentiation is antithetical to tumor development in
osteosarcoma, the molecular basis for the tightly coupled rela-
tionship between malignant transformation and loss of differ-
entiation remains poorly understood.
The biology of osteoblast differentiation has recently been
mapped in considerable detail. Runx2 (runt-related transcription
factor 2) is a key transcriptional regulator of osteogenesis
(Ogawa et al., 1993; Levanon et al., 1994; Ducy et al., 1997,
1999). Mice nullizygous for 
 
RUNX2
 
 exhibit a complete lack of
ossification (Komori et al., 1997; Otto et al., 1997), whereas
heterozygotes exhibit skeletal abnormalities comparable to
cleidocranial dysplasia (Mundlos et al., 1997). The runt family,
to which runx2 belongs, is strongly linked to human cancer
(Lund and van Lohuizen, 2002). 
 
RUNX1 (AML1)
 
 is mutated in
human leukemia, and mice expressing loss-of-function runx1
mutants are prone to leukemia (Perry et al., 2002). 
 
RUNX3
 
 is
subject to inactivating mutations or promoter hypermethylation
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in gastric cancers (Li et al., 2002). Runx2 physically inter-
acts with the retinoblastoma tumor suppressor protein (pRb;
Thomas et al., 2001), which is mutated in up to 60% of osteo-
sarcomas (Toguchida et al., 1989). Finally, runx2 expression
varies with cell cycle status and may regulate osteoblast prolif-
eration by unknown mechanisms (Pratap et al., 2003).
In this study, we investigated the effects of osteogenic
differentiation on proliferation and growth arrest, and their dis-
ruption in osteosarcomas. Consistent with a role in suppression
of proliferation, runx2 protein was absent or nonfunctional in
six out of seven osteosarcoma cell lines. Both spontaneous and
induced osteoblast differentiation are associated with increased
p27
 
KIP1
 
 mRNA and protein expression. Ectopic expression of
runx2 induced an Rb- and p27
 
KIP1
 
-dependent growth arrest.
This was due in part to increased expression of p27
 
KIP1
 
 protein,
which inhibited S-phase Cdk complexes and the dephosphory-
lation of pRb. Interestingly, runx2 is shown to interact prefer-
entially with the hypophosphorylated form of pRb, a known
coactivator of runx2. Although p27
 
KIP1
 
 expression is associated
with osteoblast differentiation, loss of p27
 
KIP1
 
 had only a minor
effect on osteoblast differentiation in vitro and in vivo. Nota-
bly, the irreversibility of both the osteogenic phenotype and
terminal cell cycle exit in vitro is dependent on expression of
p27
 
KIP1
 
. Immunohistochemical analysis of human osteosarco-
mas confirmed that expression of p27
 
KIP1
 
 was lost as tumors
lost evidence of osteogenic differentiation. Together, these data
suggest that runx2 establishes a terminally differentiated state
through Rb- and p27
 
KIP1
 
-dependent mechanisms, and that these
processes are disrupted in osteosarcomas.
 
Results
 
Characterization of the osteoblast 
phenotype in a panel of osteosarcoma 
cell lines
 
We first used transcriptional profiling to objectively character-
ize the differentiation state of a panel of osteosarcoma cell lines
(SAOS2, MG63, B143, HOS, SJSA, and G292) relative to an
osteoblast-like reference. The reference consisted of primary
stromal stem cells in which expression of markers of the ma-
ture osteoblast phenotype was induced by culture in the pres-
ence of ascorbic acid, dexamethasone, and inorganic phosphate
(Gronthos et al., 2003). These markers include runx2, osterix,
osteocalcin, and the ability to mineralize in vitro. Consistent
with a transformed state, several putative oncogenes, including
FOS and cyclins A1, B2, E1, and D1 (Fig. 1 A), were com-
monly overexpressed in osteosarcoma cell lines, whereas the
Cdk inhibitors p16
 
INK4A
 
 and p57
 
KIP2
 
 were relatively underex-
pressed. Shown in Fig. 1 A is the expression pattern of 16
bone-related genes selected from a previously published mi-
croarray study on the osteoblast phenotype (Balint et al., 2003).
Twelve genes, including the key osteoblast transcription factor,
 
RUNX2
 
, were underexpressed across all osteosarcoma cell
lines relative to our osteoblastic reference. Osteocalcin, a late
and specific osteoblast marker not represented on our arrays,
was undetectable by RT-PCR in the osteosarcoma lines (not
depicted). Overall, the average median expression of 16 osteo-
blast-related genes in the osteosarcoma cell lines was reduced
to 38 
 

 
 8% of the osteoblastic reference.
The pattern of gene expression observed in osteosarco-
mas suggests a loss or reduction in activity of runx2, a key tran-
scriptional regulator of osteoblast differentiation. To assess ac-
tivity of the runx2 pathway in the osteosarcoma cell lines,
we measured endogenous runx2 transcriptional activity using
an osteoblast-specific promoter–luciferase construct, 6ose2-luc
(Ducy and Karsenty, 1995), consisting of six tandem repeats of
the osteocalcin runx2 binding site. A mutant control containing
a dinucleotide substitution in the runx2 binding sites was used,
abolishing runx2 binding and activity (Ducy and Karsenty,
1995). The ratio of wild-type to mutant reporter activity there-
fore reflects endogenous runx2 function, and it was markedly
reduced in all seven osteosarcoma cell lines, to levels compara-
ble to that observed in fibroblasts (CCL-7625; Fig. 1 B). A pos-
itive control derived from an osteogenic osteoma (CCL-7672)
demonstrated runx2 activity 80-fold higher than in CCL-7625
cells. Similar results were observed with native osteopontin
and osteocalcin promoter–luciferase constructs (unpublished
data). The effect of ectopically expressing the osteoblast-spe-
cific MASN isoform of runx2 (hereafter runx2) on reporter ac-
tivity was studied (Fig. 1 C). Ectopic expression of runx2 in-
creased reporter activity 10–60-fold in some osteosarcoma cell
lines, suggesting that endogenous levels of runx2 were limiting
for transcriptional activity in these cell lines.
 
Lack of correlation between runx2 
protein levels and transcriptional activity
 
There was little or no correlation between runx2 protein levels
and transcriptional activity. Immunoblot analysis of endoge-
nous runx2 protein demonstrated low levels in five out of seven
cell lines (Fig. 1 D, top and middle). The upper band represents
the MRIPV isoform of runx2, whereas the faster migrating
band in SAOS2 represents the osteoblast-specific MASN iso-
form (unpublished data). The MRIPV isoform strongly induces
AP activity but not osteocalcin, whereas the MASN isoform
more potently activates osteocalcin but not AP (Harada et al.,
1999). Consistent with the results of the transcriptional assays,
no runx2 protein was detectable by Western blot in G292 cells,
which showed the greatest induction of transcription by ectopic
runx2 (Fig. 1 D). In contrast, abundant endogenous runx2 pro-
tein was present in SAOS2 cells. The striking contrast between
protein levels and intrinsic activity of runx2 in SAOS2 cells is
highlighted by comparison with protein levels in the osteoblas-
tic control, although osteoblast gene expression is 5.6 
 

 
 2.9–
fold higher in the reference than in SAOS2 cells. We have con-
firmed that no mutations exist in the genomic sequences of
runx2 in SAOS2 cells or any other cell line in this study. Thus,
some osteosarcomas, such as G292, appear to lack functional
runx2, whereas others, such as SAOS2, appear unable to acti-
vate transcription of runx2-dependent genes even when ectopic
runx2 is supplied. Interestingly, we observed that all lines re-
sponsive to ectopic runx2 express pRb, whereas those that fail
to respond express no or low levels of this known runx2 coacti-
vator. Furthermore, some pRb-positive cell lines show only
limited activation in response to runx2 expression, suggesting
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that additional factors influence the activity of runx2 in osteo-
sarcoma cell lines (Fig. 1 D). Together, these data confirm
gathering evidence that runx2 activity is critically dependent on
cofactors or posttranslational modifications, and that oncogenic
transformation results in consistent dysregulation of runx2 ac-
tivity by multiple mechanisms.
 
Runx2 inhibits cell growth through 
p27
 
KIP1
 
 and pRb
 
It appears that normal runx2 function is incompatible with ma-
lignant transformation of osteoblastic cells. To determine why,
we examined the effect of reexpression of runx2 in G292 cells.
As shown in Fig. 1 (B and C), in G292 cells runx2 levels ap-
peared to be rate limiting for transcriptional activity. This sug-
gests that the molecular apparatus for full runx2 activity, includ-
ing any potential tumor suppressor functions, exists in G292
cells. Consistent with this idea, ectopic expression of runx2 sup-
pressed cell growth (Fig. 2 A). In contrast, this effect was not
seen in SAOS2 cells, in which forced expression of runx2 had
little effect on transcriptional activity. Because SAOS2 lacks
functional pRb, whereas G292 has wild-type pRb, we hypothe-
sized that the lack of pRb may account for the inability of runx2
to reduce the proliferative capacity of these cells. Indeed, when
overexpressed in wild-type and 
 
RB
 

 
/
 

 
 3T3 cell lines, runx2 sup-
pressed colony numbers of 3T3 cells by 60–90%, an effect de-
pendent on pRb (unpublished data). To study this effect further,
we used two runx2 constructs containing transactivation do-
main mutations. One of these (27ala) lacks transcriptional activ-
ity, whereas the other (3ala) possesses wild-type activity
(Thirunavukkarasu et al., 1998). Introduction of these con-
structs into 3T3 cells showed that the colony suppression activ-
ity of runx2 is due to a G1 cell cycle arrest dependent on tran-
scriptional activity and pRb (Fig. 2 B). Runx2 was ectopically
expressed in primary human fibroblasts (CCL-211 and IMR90)
and osteosarcoma cell lines (U2OS and SAOS2), using adeno-
viral vectors. As expected, runx2 inhibited the S-phase fraction
of fibroblastic but not osteosarcoma cells. Initial studies of cell
cycle protein expression in these transfected cells revealed a
specific induction of p27
 
KIP1
 
 protein but no effect on p21
 
CIP1
 
(Fig. 2 C). Coimmunoprecipitation from CCL-211 cells showed
that p27
 
KIP1
 
 was strongly associated with cyclin A and Cdk2
(Fig. 2 D), suppressed in vitro kinase activity of cyclin A–Cdk2
complexes (Fig. 2 E), and was accompanied by dephosphoryla-
tion of endogenous pRb (Fig. 2 E). We have shown previously
that pRb binds and coactivates runx2 (Thomas et al., 2001). We
hypothesized that a feed-forward loop, integrating progressive
cell cycle withdrawal and differentiation, would be completed if
runx2 specifically interacted with the hypophosphorylated form
of pRb. This is the case (Fig. 2 F). Collectively, these data are
consistent with the transcriptional induction of growth arrest by
runx2 through an Rb- and p27
 
KIP1
 
-dependent mechanism that is
reinforced by coactivation of runx2 by direct interactions with
the hypophosphorylated form of pRb.
 
A role for p27
 
KIP1
 
 in osteogenic 
differentiation
 
The data described above suggest a role for p27
 
KIP1
 
 and pRb in
mediating runx2-dependent proliferation arrest. We have previ-
ously reported a role for pRb in runx2-dependent expression of
differentiation-related genes, and so wished to determine the
physiologic significance of p27
 
KIP1
 
 in osteoblast differentiation.
As reported previously (Drissi et al., 1999), osteoblast differen-
tiation in vitro is associated with increased expression of
p27
 
KIP1
 
 (Fig. 3 A). Bone morphogenetic proteins (BMPs) are
powerful osteoinductive agents whose effects are mediated by
runx2 (Tsuji et al., 1998; Gori et al., 1999). Treatment of mu-
rine embryonic fibroblasts (MEFs) with a synthetic BMP4/7
fusion protein induced osteoblast differentiation (and cell cycle
Figure 1. Runx2-dependent osteogenic differ-
entiation is disrupted in osteosarcoma cell lines.
(A) Gene expression arrays were performed
using RNA extracted from confluent cultures of
SAOS2, MG63, HOS, B143, SJSA, and
G292 cell lines, normalized to reference RNA
as described in Materials and methods section.
Data presented are the median log-transformed
data for six cell lines. (B) Cells were transfected
with 6ose2-luc (or with 6ose2mut-luc) and cy-
tomegalo virus (CMV)–gal plasmids. After 24 h,
luciferase activity was measured and nor-
malized to -galactosidase. The ratio of the
activity of 6ose2-luc to 6ose2mut-luc activity is
shown. Ost, osteogenic osteoma cell line CCL-
7672. Data shown are means  SEM. (C)
Cells were transfected with 6ose2-luc and
CMV-gal plasmids, with or without a runx2
expression vector. After 24 h, luciferase activity
was measured and normalized for transfection
efficiency with -galactosidase. The ratio of
luciferase activity in the presence or absence
of runx2 is shown. Data shown are means 
SEM. (D) Western blot for runx2 and pRb in
nuclear extracts from the indicated cell lines.
HOb, human primary osteoblast.
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arrest), concomitant with expression of runx2 and p27
 
KIP1
 
mRNA (Fig. 3 B). Similarly, BMP2 induced a G1 cell cycle ar-
rest in MEFs that was dependent in part on the presence of both
pRb and p27
 
KIP1
 
 (Fig. 4 A). This is consistent with a role for
runx2 in inhibition of cell proliferation and induction of differ-
entiation by BMPs. To confirm these observations in a pre-
osteoblast cell model, we used siRNA to knockdown p27
 
KIP1
 
 in
MC3T3E1 cells (Fig. 4 B). The level of knockdown achieved
was 
 

 
75%, which we consider significant because p27
 
KIP1
 
 is
believed to act as a haploinsufficient tumor suppressor gene
(Fero et al., 1998). Consistent with observations that runx2-null
osteoblasts have increased rates of proliferation (Pratap et
al., 2003), we observed an increased rate of proliferation in
MC3T3E1 cells in which p27
 
KIP1
 
 was reduced. BMP2 treat-
ment of MC3T3E1 cells expressing a control siRNA vector re-
sulted in a 42% reduction in S-phase cells, compared with a
17% reduction in cells expressing the p27
 
KIP1
 
 siRNA (Fig. 4 C).
Furthermore, as observed in G292 cells and 3T3 fibroblasts,
ectopic expression of runx2 suppressed growth of MC3T3E1
cells, and this effect was abolished in cells expressing siRNA
for p27
 
KIP1
 
 (Fig. 4 D; Chi square P 
 

 
 0.001). These data sug-
gest that p27
 
KIP1
 
, like pRb, plays a role in regulating basal rates
of proliferation in preosteoblasts and contributes to the growth
arrest associated with osteoblastic differentiation.
Next, we wished to determine whether p27
 
KIP1
 
 is required
for the osteoblast phenotype. Loss of p27
 
KIP1
 
 partially attenu-
ated BMP2-induced AP activity (Fig. 5 A), and both basal and
BMP2-induced expression of osteocalcin, osteopontin, and
type I collagen mRNA were reduced (but not abolished by) the
absence of p27
 
KIP1
 
 (Fig. 5 B). To determine the net effect of
loss of p27
 
KIP1
 
 in vivo, the long bones of murine wild-type and
 
p27
 
KIP1
 

 
 littermates were analyzed by histomorphometry.
There was a minor effect of loss of p27
 
KIP1
 
 on the formation of
Figure 2. Runx2 induces a growth arrest through induction of p27KIP1.
(A) Effect of ectopic expression of runx2 on colony suppression assay. (B)
Retroviral vectors expressing runx2 27ala or runx2 3ala were used to infect
3T3 or RB/ 3T3 cells, followed by selection for 3 d in 2 g/ml puromycin.
Cell cycle profile was determined by flow cytometry. (C) IMR90, CCL-211,
SAOS2, and U2OS cells were infected with adenoviral constructs expressing
FLAG-tagged runx2. Western blot for runx2, p27KIP1, and p21CIP1. The per-
centage of cells in S-phase, derived from parallel cultures subjected to DNA
analysis by flow cytometry, is indicated (bottom). (D) CCL-211 cells were
infected with adenoviral constructs expressing runx2. Cyclin A immunopre-
cipitates were subjected to Western blot for p27KIP1, Cdk2, and cyclin A. The
bottom panel is directly blotted for p27KIP1. Asterisks indicate Ig heavy chain
bands. (E) Cyclin A immunoprecipitates assayed for kinase activity in the
presence of runx2. CCL-211 cells were treated as in C. Direct Western blot
for Rb, cyclin A, cyclin E, Cdk2, p27KIP1, p21CIP1, runx2, and GFP to demon-
strate equal titers of virus in each culture. (F) Runx2 binds the hypophosphor-
ylated form of pRb. COS-7 cells were transfected with vector, pRb, and HA-
tagged pRb. A pulldown was performed using GST-runx2. Input is 5% of that
used for the pulldown. ppRb, phosphorylated species of pRb. Black lines
indicate that intervening lanes have been spliced out.
Figure 3. Osteogenic differentiation in vitro is associated with induction of
p27KIP1 mRNA and protein. (A) MC3T3E1 cells were cultured in differentiation
media containing 50 g/ml ascorbic acid and 2 mM -glycerophosphate.
(top) Western blot of p27KIP1 protein after 2–8 d in differentiation media.
(bottom) Alizarin red staining of mineralized cultures over 3–12 d under
identical conditions. (B) Murine embryonic fibroblasts (MEFs) cultured in the
presence of a BMP4/7 fusion protein for 14 d. (top) Induction of AP activity.
Data shown are means  SEM. (bottom left) Alizarin red staining for miner-
alization. (bottom right) RT-PCR for runx2, p27KIP1, p21CIP1, and glyceralde-
hyde phosphate dehydrogenase (GAPDH). Fold changes in gene expression
relative to GAPDH are given below each panel.
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unmineralized bone (osteoid), both as a function of total bone
volume and as measured by osteoid thickness (Fig. 5 C). This
effect was not a result of accelerated mineralization caused by
loss of p27
 
KIP1
 
, because there was no evidence of altered min-
eral apposition rate as measured directly by dual calcein la-
beling. Osteoblast and osteoclast numbers were unchanged
(unpublished data). Because osteoclasts do not resorb unminer-
alized osteoid (Chambers et al., 1985), any defect in osteoclast
function is unlikely to account for the reduction in osteoid.
These data are consistent with a very minor effect of loss of
p27
 
KIP1
 
 on osteoblast differentiation and function.
 
p27
 
KIP1
 
 is needed for terminal cell cycle 
egress
 
p27
 
KIP1
 
 plays a key role in terminal cell cycle exit in osteosar-
coma cells (Alexander and Hinds, 2001). Because terminal
differentiation is associated with permanent cell cycle with-
drawal, we tested whether MEF cultures lacking p27
 
KIP1
 
 could
reenter the cell cycle after culture under prolonged differenti-
ating conditions. There was no prior difference in cell cycle
profile of littermate wild-type or 
 
p27
 
KIP1
 

 
/
 

 
 preconfluent early
passage MEFs (unpublished data). However, although wild-
type MEFs postdifferentiation grew poorly after passage,
MEFs lacking p27
 
KIP1
 
 proliferated robustly (Fig. 6 A). This
suggests a role for p27
 
KIP1
 
 in mediating the irreversibility of
the postconfluent state. However, wild-type undifferentiated
MEFs also failed to reenter the cell cycle, probably because
p27
 
KIP1
 also accumulated in untreated cultures upon conflu-
ence (Hirano et al., 2001; and unpublished data). Consistent
with an additional effect of BMP2 upon p27KIP1, the degree of
growth inhibition after passage was greater in cultures treated
with BMP2 (Fig. 6 A). Moreover, even postdifferentiated
MEFs lacking p27KIP1 demonstrated a reduction in cell growth
when passaged after BMP2 treatment, indicating that p27KIP1
contributes to (but is not solely responsible for) terminal
growth arrest. We have not observed compensatory increases
in p21CIP1 or p57KIP2 in p27KIP1-null cultures (unpublished data),
and the mechanisms accounting for the residual effects are not
known.
Reentry into the cell cycle of BMP2-treated cultures was
associated with loss of differentiation. Compared with wild-
type cultures, BMP2-treated p27KIP1-null cultures rapidly lost
expression of osteocalcin within 2 d of passage (Fig. 6 B).
Additionally, the number of AP-positive cells was 20-fold
greater in wild-type compared with p27KIP1/ cultures (4.8 
1.8% [n  263, 10 high-power fields], compared with 0.2 
0.1% AP-positive cells [n  2039]). This suggests that termi-
nal cell cycle exit, in this case dependent on p27KIP1, is required
for maintenance of the differentiated state.
Permanent cell cycle withdrawal is a feature of both se-
nescence and terminal differentiation (Goldstein, 1990; Sellers
et al., 1998). Postdifferentiated wild-type MEFs assumed a bi-
nucleated, enlarged, flattened morphology reminiscent of repli-
cative senescence. Whether differentiated or not, significant
numbers of postconfluent wild-type MEFs stained for senes-
cence-associated -galactosidase activity (Dimri et al., 1995).
This effect was greater in cultures that had been treated with
BMP2 (Fig. 6 D). In contrast, MEFs lacking p27KIP1 did not
stain for senescence-associated -galactosidase and morpho-
logically resembled undifferentiated cultures. Although the ef-
fects of both BMP2 and p27KIP1 were independently statisti-
cally significant, the interaction between these factors failed to
reach significance, perhaps because of the powerful effect of
confluence on accumulation of p27KIP1 in both treated and con-
trol cultures. Together, these data suggest that culture condi-
tions required for differentiation of MEFs (including both
BMP2 treatment and prolonged confluence), as well as expres-
sion of p27KIP1, contribute to the entry of MEFs into a senes-
cence-like state.
Figure 4. Growth arrest due to expression of runx2 or treatment with
BMP2 is reduced by knockdown of p27KIP1. (A) Primary MEFs of the indi-
cated genotypes were treated with 100 ng/ml BMP2 for 48 h followed by
flow cytometric analysis of DNA content. Data shown are the change in G1
fraction due to treatment. This experiment was repeated twice with similar
results. (B) Western blot for p27KIP1 in MC3T3E1 cells infected with a retrovirus
expressing either control siRNA or siRNA for p27KIP1. (C) DNA analysis
using flow cytometry of cultures of cells derived as described in B. (D) Colony
suppression assay of cells as described transfected with empty vector or
runx2. Each experiment was performed in triplicate.
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Expression of p27KIP1 is lost in 
osteosarcoma
We finally wished to determine whether these observations have
relevance to human osteosarcoma. p27KIP1 expression appears to
be key for cell cycle withdrawal and terminal differentiation in
osteoblasts, and integrates the functions of BMPs, pRb, and
runx2 in these processes. Regardless of the nature of the defect
in the pRb–runx2 pathway in osteosarcoma cells, the net effect
will be loss of growth restraint due to diminished expression of
p27KIP1. Consistent with this, we found negligible expression
of p27KIP1 protein in high-grade osteosarcoma cells, although
p27KIP1 was clearly seen in osteoclasts as reported previously
(Okahashi et al., 2001; Fig. 7, A and D), correlating inversely
with expression of proliferating cell nuclear antigen (PCNA;
Fig. 7, D and F, arrows). These high-grade osteosarcomas dem-
onstrated frequent mitotic figures and little differentiation, as
evidenced by osteoid production and osteocalcin expression
(Fig. 7, B and E). High-grade tumor cells expressed high levels
of PCNA, consistent with a high S-phase fraction (Fig. 7, C and
F). In contrast, in lower grade tumors with mineralizing osteoid
and lower cellularity with more normal osteoblastic morphol-
ogy, expression of both p27KIP1 and osteocalcin is evident, espe-
cially in terminally differentiated (PCNA negative) osteocytes
embedded within bone (Fig. 7, G and H, arrows). Critically,
there was a significant relationship between expression of
p27KIP1 protein and osteoblast differentiation scored by osteoid
production in a panel of 100 osteosarcomas (Fig. 7 J, P  0.05).
This effect was independent of proliferative rate, because there
was no significant relationship between PCNA expression and
p27KIP1. These data support the view that the loss of differentia-
tion of osteosarcomas, which conveys adverse prognostic signif-
icance, is associated with loss of expression of p27KIP1.
Figure 5. Role of p27KIP1 in osteoblast function.
(A) MEFs of the indicated genotypes were dif-
ferentiated in the presence of 100 ng/ml
BMP2, ascorbic acid, and -glycerophos-
phate for 7 d and analyzed for AP activity.
Data shown are means  SEM of fold change
relative to untreated wild-type controls (n  4
experiments using independently derived litter-
mate-matched cultures, each in triplicate). Ge-
notype effect significant by analysis of vari-
ance (ANOVA; P  0.01). (B) RT-qPCR
analysis of gene expression in MEFs of the in-
dicated genotypes, normalized to ARPPo. Data
shown are means  SEM. Genotype effect
significant for BMP2 induction of osteocalcin
(P  0.01) and type I collagen (P  0.05,
ANOVA), but not osteopontin. (C) Histomorpho-
metric analysis of long bones in mice between 8
and 12 wk old of the indicated genotypes.
Data shown are means  SEM. Bold-faced
data are significantly different from wild-type
littermates (P  0.05).
Figure 6. p27KIP1 is required for terminal
growth arrest in vitro. MEFs were cultured in
the presence or absence of 100 ng/ml BMP2,
ascorbic acid, and -glycerophosphate for
14 d after confluence. Cells were then passaged.
(A) 5 	 104 cells were grown under standard
culture conditions for 3 d, and then counted.
Data shown are means  SEM. (B) RT-qPCR
analysis of osteocalcin gene expression in
MEFs of the indicated genotypes 2 d after
passage. Data shown are means  SEM of
cycle number (

CT) normalized to ARPPo
and expression before passage. The interaction
between BMP2 and genotype was significant
(P  0.01, ANOVA). (C) Photomicrograph of
senescence-associated -galactosidase–stained
cultures. (i) Wild-type untreated cultures; (ii)
p27KIP1/ untreated cultures; (iii) wild-type dif-
ferentiated cultures; and (iv) p27KIP1/ differ-
entiated cultures. (D) Cells were stained for
senescence-associated (SA) -galactosidase
activity after passage and counted (200 cells
in triplicate cultures). Data shown are means 
SEM. The effect of BMP2 and genotype was
significant (P  0.01), although there was no
interaction by ANOVA.
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Discussion
The inverse relationship between proliferation and differentia-
tion in osteoblasts has been carefully documented for many
years, although the mechanisms have not been delineated.
These observations have led to the proposition that full expres-
sion of the osteoblast phenotype is necessarily associated with
terminal cell cycle exit (Stein et al., 1996; Aubin, 1998). In ac-
cord with these observations, osteoblasts lacking functional
runx2 appear to lose a growth restraint (Pratap et al., 2003).
Our data provide a mechanistic basis for these observations
(Fig. 8). Osteogenic differentiation in culture imposes a growth
restraint and, eventually, a terminal cell cycle exit resembling
senescence, through runx2-dependent induction of p27KIP1. We
and others show that osteogenic differentiation in vitro is asso-
ciated with increased expression of p27KIP1 (Drissi et al., 1999).
This leads to a pRb-dependent growth arrest through inhibition
of S-phase cyclin complexes. We have shown previously that
interactions between runx2 and pRb enhance runx2-dependent
transcriptional activity (Thomas et al., 2001). Because it is the
hypophosphorylated form of pRb that binds runx2, the induc-
tion of p27KIP1 will enhance the transactivation of runx2 by
pRb, leading to progressive growth arrest and expression of the
mature osteoblast phenotype (Fig. 8). It is likely that loss of
function of any component of this feed-forward loop will dis-
rupt both differentiation and a restraint on cell growth. Al-
though mutations have been documented in pRb in osteosar-
coma, the molecular events that affect runx2 function in cell
lines in which pRb is not affected remain unknown.
We observed a very minor defect in osteoid synthesis in
p27KIP1/ mice, accompanied by defects in BMP2-induced dif-
ferentiation in vitro, consistent with apparently normal skeletal
patterning in mice nullizygous for p27KIP1 (Fero et al., 1996;
Kiyokawa et al., 1996; Nakayama et al., 1996). It is possible that
functional redundancy allows compensation for loss of p27KIP1,
and consistent with this hypothesis, BMP2 induced an attenuated
growth arrest in p27KIP1-null fibroblasts. Although the mecha-
nisms by which BMP2 induces a growth arrest in the absence of
p27KIP1 are not known, BMP2 and runx2 have both overlapping
and distinct effects to promote osteoblast differentiation. In addi-
tion to inducing p27KIP1, BMP2 has recently been reported to in-
hibit Cdk6 levels by a SMAD-dependent mechanism (Ogasa-
wara et al., 2004).
The induction of p27KIP1 leads to more than a simple pro-
liferative arrest. Although the proliferation of early passage
MEFs was not strikingly affected by loss of p27KIP1 (Fero et al.,
1996; Kiyokawa et al., 1996; Nakayama et al., 1996; and un-
published data), we found that p27KIP1 was required to maintain
a growth-arrested state in differentiated cells. p27KIP1 has been
suggested previously to be a part of the normal timer that deter-
mines the cessation of proliferation and commitment to differ-
entiation of oligodendrocyte precursors (Casaccia-Bonnefil et
al., 1997; Durand et al., 1998). The Drosophila melanogaster
p27KIP1 homologue, dacapo, initiates terminal cessation of cell
division and differentiation, an effect that interacts genetically
with pRb (de Nooij et al., 1996; Lane et al., 1996). These data
suggest that p27KIP1 may act as a “fate switch” that, once ex-
pressed at sufficient levels, commits the osteoblast to a postmi-
totic state. Irreversible cell cycle exit is a feature of senescence,
in which p27KIP1 plays a role and which may represent a de-
fense to oncogenic transformation (Serrano et al., 1997; Sellers
Figure 7. Expression of p27KIP1, osteocalcin,
and proliferating cell nuclear antigen (PCNA)
in human osteosarcoma samples. (A–I) High-
power photomicrographs of parallel sections
from two high-grade (A–C and G–I) and one
low-grade (G–I) human osteosarcomas were
stained for p27KIP1 (A, D, and G), osteocalcin
(B, E, and H), and PCNA (C, F, and I). Arrows
in D–F indicate multinucleated osteoclast; arrows
in G–I indicate osteocytes. Bar, 50 m. (J)
Blinded quantitation of staining for p27KIP1
and PCNA in tumors with evidence of osteo-
blast differentiation (osteoid production) com-
pared with dedifferentiated tumors. Error bars
represent SEM. *, P  0.05.
Figure 8. A model for interactions between cell cycle proteins and runx2
in osteoblasts. The interaction of hypophosphorylated pRB with runx2
completes a positive feedback loop, promoting cell cycle withdrawal and
expression of the osteoblast phenotype. See Discussion section.
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et al., 1998; Alexander and Hinds, 2001; Thomas et al., 2001).
Clearly, terminal cell cycle exit, whether in response to differ-
entiation or to oncogenic events, is fundamentally inconsistent
with oncogenic transformation.
Does p27KIP1 act as a tumor suppressor in bone? In animal
models, loss of p27KIP1 is associated with infrequent spontane-
ous pituitary tumors and intestinal adenomas but accelerates
the rate of tumor formation when combined with carcinogen
exposure (Fero et al., 1998) or mutations to TP53 (Philipp-Sta-
heli et al., 2004). Interestingly, osteosarcomas were observed
in this latter study, albeit at low frequency. Consistent with a
role for p27KIP1 in osteosarcoma, the protooncogene c-Fos,
which causes osteosarcoma in mice (Grigoriadis et al., 1993),
induces cyclin A–Cdk2 activity and represses p27KIP1 in osteo-
blasts (Sunters et al., 2004). Unusually, p27KIP1 appears to act
as a haploinsufficient tumor suppressor in the mouse (Fero et
al., 1998), and, where human tumors have undergone a loss-of-
heterozygosity event, silencing of the remaining allele is rare
(Kawamata et al., 1995; Ponce-Castaneda et al., 1995). This
may be due to the dual role of p27KIP1 as an assembly factor for
G1-phase cyclin complexes as well as a stoichiometric inhibi-
tor of S-phase cyclin complexes (Sherr and Roberts, 1999). Im-
portantly, decreases in p27KIP1 protein expression have been
found in 60% of human carcinomas (Slingerland and Pagano,
2000), and are associated in breast cancer with poor prognosis
(Fredersdorf et al., 1997). Our clinical studies reveal an associ-
ation between p27KIP1 expression and loss of differentiation in
human osteosarcomas, independent of rates of proliferation per
se (Fig. 7). Loss of differentiation in sarcomas in general is a
marker of high-grade status, which in turn is associated with
worse prognosis.
Disruption of runx2-dependent transcriptional activity is
common in osteosarcoma cell lines and leads in a clinically
measurable fashion to loss of both differentiation and expres-
sion of p27KIP1 in human osteosarcomas. Although the specific
mechanisms contributing to the loss of function of runx2 are
not understood, global demethylation of osteosarcoma cell
lines results in reactivation of differentiation concomitant with
reversion of transformation (unpublished data). Methylation is
a well-described, common method of silencing tumor suppres-
sor pathways (Baylin and Herman, 2000), and the restoration
of differentiation by demethylation further supports the notion
that tumors gain a selective survival advantage by silencing
differentiation-related growth inhibitory processes. We hope
that identifying targets of methylation-induced silencing will
shed additional light on the interactions between differentiation
and cell cycle exit.
Materials and methods
Cell lines and reagents
The osteosarcoma cell lines were maintained in DME (GIBCO BRL) con-
taining 15% FCS. CCL-7625 and CCL-7672 cells were obtained from
American Type Culture Collection. MC3T3E1 cells were maintained in
MEM supplemented with 10% FCS. RB/ 3T3 and NIH3T3 cells were in-
fected with pBABEpuro retrovirus (Morgenstern and Land, 1990) express-
ing mutant constructs of runx2 (Thirunavukkarasu et al., 1998), and with
pooled clones selected with puromycin. Stable expression of constructs
was confirmed by immunoblot (unpublished data). Wild-type and RB/
MEFs with the described genotypes (wild-type and RB/) were derived
from matched littermates (gifts of T. Jacks, Massachusetts Institute of Tech-
nology, Boston, MA), and p27KIP1/ mice were obtained from J. Roberts
(Fred Hutchinson Cancer Research Center, Seattle, WA) (Fero et al.,
1996). Mineralization was induced by culture in the presence of 5 mM
-glycerophosphate and 50 g/ml ascorbic acid for 3 wk after conflu-
ence (Thomas et al., 2001). For colony suppression assays, cells (105/10-cm
plate) were transfected with constructs as indicated in Figs. 2 A and 4 D.
After 24 h, cells were selected in the presence of antibiotic (2 g/ml puro-
mycin or 1–5 g/ml neomycin) for 14–21 d. Colonies were visualized
with crystal violet. Doses of 5-aza-2-deoxycytidine were titrated in prelimi-
nary studies for each cell line to achieve growth arrest without significant
cell death, usually between 2 and 5 M.
SV-Rb and SV-HARb were used for the expression of full-length pRb
(Hinds et al., 1992). Expression constructs for runx2 were cloned into
pBABEpuro (Morgenstern and Land, 1990). The retrovirus was amplified
and purified in amphotropic packaging cell line Phoenix 293 (courtesy of
G. Nolan, Stanford University, Palo Alto, CA), according to the method of
Pear et al. (1993). Plasmids were transfected into cells with the use of Fu-
gene, according to the manufacturer’s instructions (Roche Pharmaceuti-
cals). Adenoviral constructs expressing pRb and runx2-FLAG were gener-
ated as reported previously (Thomas et al., 2001).
Cell-based assays
Luciferase assays were performed according to manufacturer’s instructions
(Promega). Where indicated (Fig. 1, B and C), results were normalized for
transfection efficiency with -galactosidase activity or protein content. AP
activity was assayed as described previously (Sellers et al., 1998). Assays
for mineralization were performed as described previously (Thomas et al.,
2001). Quantitation was performed by dissolving stained mineralized cul-
tures in 10% cetylpyridinium chloride, followed by spectrophotometric
analysis at 540 nm. Both AP activity and mineralization were normalized
to protein content (Bio-Rad Laboratories). Flow cytometry for DNA content
was performed as described previously (Thomas et al., 2001).
RT-PCR analysis of gene expression
RNA was extracted with the use of TRIzol (Invitrogen), according to the
manufacturer’s instructions. cDNA was produced from 1 g of total RNA
with the use of a commercially available kit (SUPERSCRIPT Choice system
for cDNA synthesis; GIBCO BRL). Semiquantitative PCR analysis was per-
formed after optimization. Primer sequences and PCR conditions are avail-
able on request. For quantitative RT-PCR, expression of each target gene
was normalized to expression of ARPP0 with the use of an ABI-Prism 7700
Light Cycler and SYBR Green. Optimal PCR conditions were established
for each gene in preliminary experiments.
Analysis of protein expression and kinase assays
Nuclear extracts and immunoblot analyses were performed as described
previously (Thomas et al., 2001). The following antibodies were used:
anti-FLAG antibody (M2; Sigma-Aldrich); human pRb: monoclonal anti-
body 245 (BD Biosciences); runx2: M-70 (Santa Cruz Biotechnology,
Inc.); p27KIP1: K25020 (Transduction Laboratories); and cyclin E: HE12,
cyclin A: H432, and Cdk2: M2 (Santa Cruz Biotechnology, Inc.). Horse-
radish peroxidase–conjugated secondary antibodies were used (Jackson
ImmunoResearch Laboratories) and signal was detected by ECL (NEN Life
Science Products). The GST-runx2 pulldown studies shown in Fig. 4 D
were performed as described previously (Thomas et al., 2001). Kinase as-
says were performed as described previously (Alexander and Hinds,
2001). Cyclin A was immunoprecipitated using agarose-conjugated anti-
body BF683 (Upstate Biotechnology).
Immunohistochemistry
25 paraffin-embedded osteosarcoma samples were obtained from the pa-
thology archives at St. Vincent’s Hospital Melbourne, with approval from
the Human Research Ethics Committee. 2-mm cores were punched and
then assembled into a tissue microarray. Sections were cut at 3 m and
mounted onto Superfrost Plus slides. Primary antibodies were incubated
for 30 min. For p27KIP1, clone SX53G8 (DakoCytomation) was used at 1:50.
A predilute monoclonal antibody to human osteocalcin (OC-1; Biogenex)
was used at 1:4. For PCNA, clone PC10 (DakoCytomation) was used at
1:400. The primary antibody was detected with the mouse Envision sys-
tem (DakoCytomation). Immunoreactivity was visualized with AEC chro-
mogen (DakoCytomation), using hematoxylin as a counterstain. Samples
for p27KIP1 and osteocalcin were incubated in 10 mM boiling sodium ci-
trate buffer, pH 6.0, for 2 min before staining.
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Slides were imaged using a microscope (Axioskop 2; Carl Zeiss
MicroImaging, Inc.) with a Plan-Neofluar objective (40	, 0.75 NA), and
a cooled color digital camera (RT Slider SPOT; Diagnostic Instruments)
and software (SPOT V4.0.2 for Windows). Subsequent processing of TIFF
files was undertaken in Adobe Photoshop (V7.0.1). Images were
cropped, labeled as indicated in Fig. 7, and assembled into composites
for figures after minor adjustments for contrast and color balance were ap-
plied to all parts of each image.
Microarray analysis
Total RNA from osteosarcoma and common reference cell lines was iso-
lated using phenol-chloroform extraction (TRIzol; Invitrogen) and purified
by column chromatography (RNeasy; QIAGEN). The common reference
RNA, containing pooled RNA from 11 human tumor cell lines, was pre-
pared as described previously (Pollack, 2002). Total RNA (40–50 g)
was reverse transcribed with Moloney Murine Leukemia Virus Reverse
transcriptase (Promega), in the presence of amino-allyl (AA)–modified
dUTP (Sigma-Aldrich). AA-dUTP cDNA was labeled by coupling to Cy3
and Cy5 (reference and sample, respectively) monoreactive dyes (Amer-
sham Biosciences). cDNA arrays containing 10.5 K elements represent-
ing 9,381 unique cDNA (Unigene build 172) were produced at Peter
MacCallum Cancer Centre Microarray Core facility on superamine slides
(Telechem), with a robotic arrayer (Virtek/Bio-Rad Laboratories). Labeled
probe was hybridized to the array in 3.1 	 SSC and 50% formamide at
42C for 14–16 h in a humidified and temperature-controlled chamber
(HyPro20; Thermo Hybaid). Slides were washed at room temperature with
0.5 	 SSC/0.01% SDS (for 1 min), then with 0.5 	 SSC (for 3 min), and
finally with 0.06 	 SSC (for 3 min). Scanning was performed with an Ag-
ilent G2565AA Microarray Scanner and data was extracted with Gene-
Pix Pro 4.1 software (Axon Instruments, Inc.). All array experiments, in-
cluding cell culture, were performed independently twice. A complete list
of genes is available from the authors on request. Data from each inde-
pendent experiment were averaged, and then the median obtained from
all six cell lines was used in the data shown in Fig. 1. Data were analyzed
with GeneSpring software (Silicon Genetics), and samples were normal-
ized with LOWESS (Yang et al., 2002).
Histomorphometry
Tibiae were collected from male p27KIP1/ and wild-type littermates at
16 wk of age, fixed in cold 4% paraformaldehyde in PBS overnight, and
embedded in methylmethacrylate (Sims et al., 2000). Double fluorochrome
labeling to quantitate mineral appositional rates was performed as de-
scribed previously (Sims et al., 2000). 5-m sections were stained with
toluidine blue or analyzed unstained for fluorochrome labels according to
standard procedures in the proximal tibia using the Osteomeasure system
(Osteometrics, Inc.). Tibial cortical thickness and periosteal mineral apposi-
tional rates were measured as described previously (Sims et al., 2000).
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